Biotech - Spark Newswire

1 minute read

First Wave Bio New Clinical Trial Study ‘Pilot Study To Assess Safety And Efficacy Of An Enteric Microgranule Formulation Of Adrulipase In Patients With Exocrine Pancreatic Insufficiency Due To Cystic Fibrosis.’

By Happy Mohamed

Today, 12:55 PM

https://clinicaltrials.gov/ct2/show/NCT05719311 Brief Summary:

FWBI

1 minute read

Teva Pharma Posts Lower Q4 Earnings, FY23 Outlook Within Expectations

By Vandana Singh

Today, 12:55 PM

Teva Pharmaceutical Industries Ltd’s (NYSE:TEVA) Q4 sales reached $3.88 billion, shrinking 5% Y/Y, missing the consensus of $3.93 billion. The…

TEVA

1 minute read

Why Are Creative Medical Shares Soaring Today?

By Vandana Singh

Today, 12:55 PM

Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has received Institutional Review Board approval to proceed with its Clinical Trial for Type 1…

CELZ

1 minute read

Evaxion Biotech, Pantherna Reveals Encouraging Data From mRNA-Based Cancer Vaccine

By Vandana Singh

Today, 12:55 PM

Evaxion Biotech A/S (NASDAQ:EVAX) and Pantherna Therapeutics GmbH announced a preclinical proof of concept for combining the two companies key technologies. The…

EVAX

2 minute read

Hoth Therapeutics Announces Increased Results Of Its Alzheimer’s Therapeutic HT-ALZ; Shows Cognitive Improvements In Alzheimer’s Disease Mouse Model And Results Show Reduced Anxiety And Improved Performance

By Happy Mohamed

Today, 12:55 PM

HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model and Results Show Reduced Anxiety and Improved Performance NEW YORK, Feb. 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc.

HOTH

1 minute read

Purple Biotech Q4 2023 EPS Loss Of $(0.33) Up From $(0.44) YoY. Cash And Cash Equivalents, Short- And Long-term Deposits Of $31.7M, Providing Cash Runway Into Second Half Of 2024

By Benzinga Newsdesk

Today, 12:55 PM

Purple Biotech Reports An Operating Loss Of $6.6M, Up 40.4% Y/Y

PPBT

1 minute read

PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation

By Lara Goldstein

Today, 12:55 PM

Specialty ketamine company PharmaTher Holdings Ltd.

PHRRF

1 minute read

LIXTE Biotechnology Stock Jumps As Lead Program Shows Cancer Killing Activity In Animal Models

By Vandana Singh

Today, 12:55 PM

LIXTE Biotechnology Holdings Inc (NASDAQ:LIXT) noted that a team of scientists reported that in three difficult-to-treat cancer types, LIXTE’s…

LIXT

2 minute read

Lixte Biotechnology Holdings Reports That Its Lead Clinical Compound, LB-100, Can Kill Cancer Cells Through Hyper-Stimulation Of Cell Proliferation Signals In Pre-Clinical Models; Shares Halted On Circuit Breaker To The Upside

By Happy Mohamed

Today, 12:55 PM

--THE STUDY ESTABLISHES A NOVEL CONCEPT OF "TUMOR SUPPRESSIVE DRUG RESISTANCE" --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN

LIXT